Russian study to monitor Real-World use of acalabrutinib in CLL patients

NCT ID NCT04746950

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This observational study will follow about 90 adults with chronic lymphocytic leukemia (CLL) in Russia who are prescribed acalabrutinib as part of their routine care. Researchers will collect data from medical records to see how long patients stay free of disease progression and what side effects occur. No extra tests or treatments are involved—just watching what happens in real-world practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: acalabrutinib
What this could lead to: If successful, this study could provide real-world evidence on how well acalabrutinib works and its side effects in routine clinical practice for CLL patients in Russia.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient selection and local practices. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

Research Site

Ufa, Bashkortostan Republic, 450054, Russia
Research Site

Kaliningrad, Kaliningrad Oblast, Russia
Research Site

Khabarovsk, Khabarovskiy Kray, 680009, Russia
Research Site

Syktyvkar, Komi, Russia
Research Site

Krasnoyarsk, Krasnoyarsk Region, 660022, Russia
Research Site

Saint Petersburg, Leningradskaya Oblast', 198205, Russia
Research Site

Moscow, Moscow Oblast, 125284, Russia
Research Site

Moscow, Moscow Oblast, 129110, Russia
Research Site

Nizhny Novgorod, Nizhny Novgorod Oblast, Russia
Research Site

Novosibirsk, Novosibirsk Oblast, 630091, Russia
Research Site

Yakutsk, Sakha Republic, 677008, Russia
Research Site

Saratov, Saratov Oblast, 410028, Russia
Research Site

Kaliningrad, Russia
Research Site

Nizhny Novgorod, Russia
Research Site

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.